Seminars in Hematology
Volume 45, Supplement 2 , Pages S17-S21, July 2008

Targeting FLT3 for the Treatment of Leukemia

  • Donald Small

      Affiliations

    • Corresponding Author InformationAddress correspondence to Donald Small, MD, PhD, Kyle Haydock Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, CRB1-251, 1650 Orleans St, The Johns Hopkins University, Baltimore, MD 21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 STATEMENT OF CONFLICT OF INTEREST: Research support/Principal Investigator: Imclone Systems, Ambit Biosciences, Xanthus Pharmaceuticals.

PII: S0037-1963(08)00123-6

doi:10.1053/j.seminhematol.2008.07.007

Seminars in Hematology
Volume 45, Supplement 2 , Pages S17-S21, July 2008

Article Tools

* Image Usage & Resolution